The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Retrospective analysis of baseline clinical factors associated to CDDP-nephrotoxicity in locally advanced head and neck cancer (LAHNC) patients.
 
Francesca Platini
No Relationships to Disclose
 
Francesco Barretta
No Relationships to Disclose
 
Salvatore Alfieri
No Relationships to Disclose
 
Stefano Cavalieri
No Relationships to Disclose
 
Carlo Resteghini
No Relationships to Disclose
 
Donata Galbiati
No Relationships to Disclose
 
Laura Deborah Locati
Consulting or Advisory Role - Eisai; Ipsen
Speakers' Bureau - Eisai
 
Cristiana Bergamini
No Relationships to Disclose
 
Roberta Granata
No Relationships to Disclose
 
Giuseppina Calareso
No Relationships to Disclose
 
Nicola Alessandro Iacovelli
No Relationships to Disclose
 
Pasquale Quattrone
No Relationships to Disclose
 
Fabiola Incandela
No Relationships to Disclose
 
Paolo Bossi
Honoraria - Bristol-Myers Squibb; Kyowa Hakko Kirin; Merck
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Sanofi/Regeneron
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Exelixis (Inst); Helsinn Therapeutics (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
 
Lisa F. Licitra
Consulting or Advisory Role - Amgen and Nanobiotics Sa; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group; Doxapharma; Eisai; Health & Life srl; Immuno-Oncology Hub; Incyte; Ipsen; Kura Oncology; Merck Serono; MSD; Novartis; Roche; SOBI
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Eisai (Inst); Exelixis (Inst); IRX Therapeutics (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Expert Testimony - Bayer; Doxapharma; GlaxoSmithKline; Health & Life; Ipsen; Kura Oncology; Merck Serono; MSD
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Debiopharm Group; Merck Serono; MSD; SOBI